346 related articles for article (PubMed ID: 25427282)
21. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
[TBL] [Abstract][Full Text] [Related]
23. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
24. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W; Uijen MJM; Krens SD; Dijkema T; Willems SM; Jonker MA; Pegge SAH; van Engen-van Grunsven ACH; van Herpen CML
Eur J Cancer; 2022 Jan; 161():128-137. PubMed ID: 34920917
[TBL] [Abstract][Full Text] [Related]
25. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib.
Goyal A; Jacobsen AA; O'Leary D; Watson A; Luikart S; Gaddis KJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941722
[TBL] [Abstract][Full Text] [Related]
26. Reversible Cabozantinib-Induced Cardiomyopathy.
Alhussein M; Hotte SJ; Leong DP
Can J Cardiol; 2019 Apr; 35(4):544.e1-544.e2. PubMed ID: 30935646
[TBL] [Abstract][Full Text] [Related]
27. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
[TBL] [Abstract][Full Text] [Related]
28. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
[TBL] [Abstract][Full Text] [Related]
29. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
Tomita Y; Tatsugami K; Nakaigawa N; Osawa T; Oya M; Kanayama H; Nakayama Kondoh C; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Tanaka S; Kimura A; Tamada S
Int J Urol; 2020 Nov; 27(11):952-959. PubMed ID: 32789967
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib for the treatment of advanced medullary thyroid cancer.
Nagilla M; Brown RL; Cohen EE
Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
32. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
Lee RJ; Saylor PJ; Michaelson MD; Rothenberg SM; Smas ME; Miyamoto DT; Gurski CA; Xie W; Maheswaran S; Haber DA; Goldin JG; Smith MR
Clin Cancer Res; 2013 Jun; 19(11):3088-94. PubMed ID: 23553848
[TBL] [Abstract][Full Text] [Related]
33. U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
Singh H; Brave M; Beaver JA; Cheng J; Tang S; Zahalka E; Palmby TR; Venugopal R; Song P; Liu Q; Liu C; Yu J; Chen XH; Wang X; Wang Y; Kluetz PG; Daniels SR; Papadopoulos EJ; Sridhara R; McKee AE; Ibrahim A; Kim G; Pazdur R
Clin Cancer Res; 2017 Jan; 23(2):330-335. PubMed ID: 27793960
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
Rabinowits G; Lezcano C; Catalano PJ; McHugh P; Becker H; Reilly MM; Huang J; Tyagi A; Thakuria M; Bresler SC; Sholl LM; Shapiro GI; Haddad R; DeCaprio JA
Oncologist; 2018 Jul; 23(7):814-821. PubMed ID: 29445030
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
37. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.
Viola D; Cappagli V; Elisei R
Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240
[TBL] [Abstract][Full Text] [Related]
38. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.
Schwartz G; Darling JO; Mindo M; Damicis L
Target Oncol; 2020 Aug; 15(4):549-565. PubMed ID: 32770441
[TBL] [Abstract][Full Text] [Related]
39. Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
Cappagli V; Moriconi D; Bonadio AG; Giannese D; La Manna G; Egidi MF; Comai G; Vischini G; Bottici V; Elisei R; Viola D
J Endocrinol Invest; 2021 Jan; 44(1):95-103. PubMed ID: 32363491
[TBL] [Abstract][Full Text] [Related]
40. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Hellerstedt BA; Vogelzang NJ; Kluger HM; Yasenchak CA; Aftab DT; Ramies DA; Gordon MS; Lara P
Clin Lung Cancer; 2019 Mar; 20(2):74-81.e1. PubMed ID: 30528315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
